DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF LEVODOPA .3. INFLUENCE OF DOSE ON PHARMACOKINETIC BEHAVIOR OF LEVODOPA IN DOGS AND PARKINSONIAN-PATIENTS

被引：34

作者：

SASAHARA, K

NITANAI, T

HABARA, T

MORIOKA, T

NAKAJIMA, E

机构：

来源：

JOURNAL OF PHARMACEUTICAL SCIENCES | 1980年 / 69卷 / 12期

关键词：

D O I：

10.1002/jps.2600691205

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：1374 / 1378

页数：5

共 10 条

[1]

BARBEAU A, 1969, CAN MED ASSOC J, V101, P791

[2] AROMATIC AMINO ACIDS AND MODIFICATION OF PARKINSONISM [J].

COTZIAS, GC ;

VANWOERT, MH ;

SCHIFFER, LM .

NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (07) :374-&

[3]

DIXON WJ, 1977, BMDP BIOMEDICAL COMP

[4]

HANANO M, 1972, 2ND S MET EFF TOX DR

[5] DOPAMIN (3-HYDROXYTYRAMIN) IM ZENTRALNERVENSYSTEM UND SEINE BEZIEHUNG ZUM PARKINSON-SYNDROM DES MENSCHEN [J].

HORNYKIEWICZ, O .

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1962, 87 (36) :1807-+

[6]

KLAWANS HL, 1969, DIS NERV SYST, V30, P737

[7] TREATMENT OF PARKINSONS SYNDROME WITH L DIHYDROXYPHENYLALANINE (LEVODOPA) [J].

MCDOWELL, F ;

LEE, JE ;

SWIFT, T ;

SWEET, RD ;

OGSBURY, JS ;

KESSLER, JT .

ANNALS OF INTERNAL MEDICINE, 1970, 72 (01) :29-+

[8] DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF LEVODOPA .2. BIOAVAILABILITY OF MARKETED LEVODOPA PREPARATIONS IN DOGS AND PARKINSONIAN-PATIENTS [J].

SASAHARA, K ;

NITANAI, T ;

HABARA, T ;

MORIOKA, T ;

NAKAJIMA, E .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (03) :261-265

[9]

SASAHARA K, 1978, Annual Report of Sankyo Research Laboratories, V30, P65

[10] TREATMENT OF PARKINSONISM WITH LEVODOPA [J].

YAHR, MD ;

DUVOISIN, RC ;

SCHEAR, MJ ;

BARRETT, RE ;

HOEHN, MM .

ARCHIVES OF NEUROLOGY, 1969, 21 (04) :343-&

← 1 →